Compare Huntington Ingalls Industries Inc (HII) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Huntington Ingalls Industries Inc vs IDEXX Laboratories, Inc. — how do they compare? Huntington Ingalls Industries Inc trades at $264.76 (market cap $10.44B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.9× Huntington Ingalls Industries Inc's market cap, and Huntington Ingalls Industries Inc pays a 2.08% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Huntington Ingalls Industries Inc for 28 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| HII | IDXX | |
|---|---|---|
Market Cap | $10.44B | $40.43B |
Volume | 440,462 | 692,164 |
Sector | Industrials | Health |
52-Week High | $453.73 | $766.68 |
52-Week Low | $257.05 | $504.70 |
Typical Hold Time | 28 Days | 46 Days |
Enterprise Value | $13.37B | $41.32B |
Dividend Yield | 2.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HII trades at $264.51, up 1.47% with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with a $12.48B revenue, 5.01% net margin, and attractive valuation (P/E 15.78, P/S 0.79). Recent contract wins including a $5.1B aircraft carrier overhaul and 10 unmanned vessel orders provide strong revenue visibility. Analyst consensus is mixed with 40.7% buy ratings but a $363.67 price target suggesting 37% upside potential.
The stock presents value opportunity with strong defense sector positioning and $57.3B backlog, though technical weakness and execution risks on major contracts warrant caution. Upside catalysts include continued earnings beats and contract execution, while risks involve defense budget uncertainty and project delays. Current levels offer entry point for long-term investors given the significant discount to analyst targets.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
